Compare RMD & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMD | IQV |
|---|---|---|
| Founded | 1989 | 1982 |
| Country | United States | United States |
| Employees | 10600 | 93000 |
| Industry | Medical/Dental Instruments | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4B | 28.6B |
| IPO Year | N/A | 2013 |
| Metric | RMD | IQV |
|---|---|---|
| Price | $206.56 | $165.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | ★ $292.56 | $227.13 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $10.60 | $6.77 |
| Revenue Next Year | $7.41 | $5.89 |
| P/E Ratio | ★ $25.61 | $100.86 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $198.61 | $137.33 |
| 52 Week High | $293.81 | $247.05 |
| Indicator | RMD | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 44.19 |
| Support Level | $198.63 | $159.08 |
| Resistance Level | $260.21 | $182.20 |
| Average True Range (ATR) | 4.70 | 5.92 |
| MACD | 1.20 | -0.83 |
| Stochastic Oscillator | 61.39 | 16.93 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.